Psychotropic drugs and CYP2D6 in late-life psychiatric and neurological disorders. What do we know?

Davide Seripa, Madia Lozupone, Eleonora Stella, Giulia Paroni, Paola Bisceglia, Maddalena La Montagna, Grazia D’onofrio, Carolina Gravina, Maria Urbano, Maria Giovanna Priore, Angela Lamanna, Antonio Daniele, Antonello Bellomo, Giancarlo Logroscino, Antonio Greco, Francesco Panza

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Introduction: Late-life psychiatric and neurological disorders (LLPND) are interesting models to understand the potential role of pharmacogenetics in drug management, since several pharmacological approaches for treating LLPND have proven to be ineffective or deleterious, thus resulting in therapeutic failures (TF) and adverse drug reactions (ADR). Common variants in the genes encoding the cytochrome P450 (CYP) enzyme system, the ‘engine room’ of drug metabolism, together with well-known age-related increased polypharmacy also contributed to the prevalence of TF and ADR observed in these patients, also rising number and time of hospital readmissions and rate of institutionalizations. Areas covered: The genetics of CYP and how it may be used for the management of the outcomes of the most frequent drugs (antidepressants, antipsychotics, anticholinesterase inhibitors, and anxiolytics) used in LLPND. Expert opinion: Tailored CYP-based pharmacological treatments of LLPND will reduce TFs and ADRs, improving patient’s life, reducing number and dosage of administered drugs, and the number and duration of hospital readmissions, saving costs for clinical management of LLPND. Pharmacokinetic interactions are less predictable than pharmacodynamic ones and several requests are made to regulatory organisms for the pharmacological management of frail older patients affected by LLPND.

Original languageEnglish
Pages (from-to)1373-1385
Number of pages13
JournalExpert Opinion on Drug Safety
Volume16
Issue number12
DOIs
Publication statusPublished - Dec 2 2017

Fingerprint

Cytochrome P-450 CYP2D6
Psychotropic Drugs
Nervous System Diseases
Psychiatry
Cytochrome P-450 Enzyme System
Patient Readmission
Pharmacology
Drug-Related Side Effects and Adverse Reactions
Pharmaceutical Preparations
Polypharmacy
Institutionalization
Pharmacogenetics
Cholinesterase Inhibitors
Anti-Anxiety Agents
Expert Testimony
Antidepressive Agents
Antipsychotic Agents
Therapeutics
Pharmacokinetics
Costs and Cost Analysis

Keywords

  • Adverse drug reaction
  • cytochrome P450
  • late-life neurological disorders
  • late-life psychiatric disorders
  • therapeutic failure

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Psychotropic drugs and CYP2D6 in late-life psychiatric and neurological disorders. What do we know? / Seripa, Davide; Lozupone, Madia; Stella, Eleonora; Paroni, Giulia; Bisceglia, Paola; La Montagna, Maddalena; D’onofrio, Grazia; Gravina, Carolina; Urbano, Maria; Priore, Maria Giovanna; Lamanna, Angela; Daniele, Antonio; Bellomo, Antonello; Logroscino, Giancarlo; Greco, Antonio; Panza, Francesco.

In: Expert Opinion on Drug Safety, Vol. 16, No. 12, 02.12.2017, p. 1373-1385.

Research output: Contribution to journalReview article

Seripa, D, Lozupone, M, Stella, E, Paroni, G, Bisceglia, P, La Montagna, M, D’onofrio, G, Gravina, C, Urbano, M, Priore, MG, Lamanna, A, Daniele, A, Bellomo, A, Logroscino, G, Greco, A & Panza, F 2017, 'Psychotropic drugs and CYP2D6 in late-life psychiatric and neurological disorders. What do we know?', Expert Opinion on Drug Safety, vol. 16, no. 12, pp. 1373-1385. https://doi.org/10.1080/14740338.2017.1389891
Seripa, Davide ; Lozupone, Madia ; Stella, Eleonora ; Paroni, Giulia ; Bisceglia, Paola ; La Montagna, Maddalena ; D’onofrio, Grazia ; Gravina, Carolina ; Urbano, Maria ; Priore, Maria Giovanna ; Lamanna, Angela ; Daniele, Antonio ; Bellomo, Antonello ; Logroscino, Giancarlo ; Greco, Antonio ; Panza, Francesco. / Psychotropic drugs and CYP2D6 in late-life psychiatric and neurological disorders. What do we know?. In: Expert Opinion on Drug Safety. 2017 ; Vol. 16, No. 12. pp. 1373-1385.
@article{9658585cc6884c9d97c26d6e2b0d90a3,
title = "Psychotropic drugs and CYP2D6 in late-life psychiatric and neurological disorders. What do we know?",
abstract = "Introduction: Late-life psychiatric and neurological disorders (LLPND) are interesting models to understand the potential role of pharmacogenetics in drug management, since several pharmacological approaches for treating LLPND have proven to be ineffective or deleterious, thus resulting in therapeutic failures (TF) and adverse drug reactions (ADR). Common variants in the genes encoding the cytochrome P450 (CYP) enzyme system, the ‘engine room’ of drug metabolism, together with well-known age-related increased polypharmacy also contributed to the prevalence of TF and ADR observed in these patients, also rising number and time of hospital readmissions and rate of institutionalizations. Areas covered: The genetics of CYP and how it may be used for the management of the outcomes of the most frequent drugs (antidepressants, antipsychotics, anticholinesterase inhibitors, and anxiolytics) used in LLPND. Expert opinion: Tailored CYP-based pharmacological treatments of LLPND will reduce TFs and ADRs, improving patient’s life, reducing number and dosage of administered drugs, and the number and duration of hospital readmissions, saving costs for clinical management of LLPND. Pharmacokinetic interactions are less predictable than pharmacodynamic ones and several requests are made to regulatory organisms for the pharmacological management of frail older patients affected by LLPND.",
keywords = "Adverse drug reaction, cytochrome P450, late-life neurological disorders, late-life psychiatric disorders, therapeutic failure",
author = "Davide Seripa and Madia Lozupone and Eleonora Stella and Giulia Paroni and Paola Bisceglia and {La Montagna}, Maddalena and Grazia D’onofrio and Carolina Gravina and Maria Urbano and Priore, {Maria Giovanna} and Angela Lamanna and Antonio Daniele and Antonello Bellomo and Giancarlo Logroscino and Antonio Greco and Francesco Panza",
year = "2017",
month = "12",
day = "2",
doi = "10.1080/14740338.2017.1389891",
language = "English",
volume = "16",
pages = "1373--1385",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Taylor and Francis Ltd.",
number = "12",

}

TY - JOUR

T1 - Psychotropic drugs and CYP2D6 in late-life psychiatric and neurological disorders. What do we know?

AU - Seripa, Davide

AU - Lozupone, Madia

AU - Stella, Eleonora

AU - Paroni, Giulia

AU - Bisceglia, Paola

AU - La Montagna, Maddalena

AU - D’onofrio, Grazia

AU - Gravina, Carolina

AU - Urbano, Maria

AU - Priore, Maria Giovanna

AU - Lamanna, Angela

AU - Daniele, Antonio

AU - Bellomo, Antonello

AU - Logroscino, Giancarlo

AU - Greco, Antonio

AU - Panza, Francesco

PY - 2017/12/2

Y1 - 2017/12/2

N2 - Introduction: Late-life psychiatric and neurological disorders (LLPND) are interesting models to understand the potential role of pharmacogenetics in drug management, since several pharmacological approaches for treating LLPND have proven to be ineffective or deleterious, thus resulting in therapeutic failures (TF) and adverse drug reactions (ADR). Common variants in the genes encoding the cytochrome P450 (CYP) enzyme system, the ‘engine room’ of drug metabolism, together with well-known age-related increased polypharmacy also contributed to the prevalence of TF and ADR observed in these patients, also rising number and time of hospital readmissions and rate of institutionalizations. Areas covered: The genetics of CYP and how it may be used for the management of the outcomes of the most frequent drugs (antidepressants, antipsychotics, anticholinesterase inhibitors, and anxiolytics) used in LLPND. Expert opinion: Tailored CYP-based pharmacological treatments of LLPND will reduce TFs and ADRs, improving patient’s life, reducing number and dosage of administered drugs, and the number and duration of hospital readmissions, saving costs for clinical management of LLPND. Pharmacokinetic interactions are less predictable than pharmacodynamic ones and several requests are made to regulatory organisms for the pharmacological management of frail older patients affected by LLPND.

AB - Introduction: Late-life psychiatric and neurological disorders (LLPND) are interesting models to understand the potential role of pharmacogenetics in drug management, since several pharmacological approaches for treating LLPND have proven to be ineffective or deleterious, thus resulting in therapeutic failures (TF) and adverse drug reactions (ADR). Common variants in the genes encoding the cytochrome P450 (CYP) enzyme system, the ‘engine room’ of drug metabolism, together with well-known age-related increased polypharmacy also contributed to the prevalence of TF and ADR observed in these patients, also rising number and time of hospital readmissions and rate of institutionalizations. Areas covered: The genetics of CYP and how it may be used for the management of the outcomes of the most frequent drugs (antidepressants, antipsychotics, anticholinesterase inhibitors, and anxiolytics) used in LLPND. Expert opinion: Tailored CYP-based pharmacological treatments of LLPND will reduce TFs and ADRs, improving patient’s life, reducing number and dosage of administered drugs, and the number and duration of hospital readmissions, saving costs for clinical management of LLPND. Pharmacokinetic interactions are less predictable than pharmacodynamic ones and several requests are made to regulatory organisms for the pharmacological management of frail older patients affected by LLPND.

KW - Adverse drug reaction

KW - cytochrome P450

KW - late-life neurological disorders

KW - late-life psychiatric disorders

KW - therapeutic failure

UR - http://www.scopus.com/inward/record.url?scp=85033390457&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85033390457&partnerID=8YFLogxK

U2 - 10.1080/14740338.2017.1389891

DO - 10.1080/14740338.2017.1389891

M3 - Review article

C2 - 29025271

AN - SCOPUS:85033390457

VL - 16

SP - 1373

EP - 1385

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - 12

ER -